EMISPHERE TECHNOLOGIES INC
EMISPHERE TECHNOLOGIES INC (EMIS): 4 pipeline candidates · ~10 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.9 months
D/E -1.03 · 14% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for EMISPHERE TECHNOLOGIES INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$160.1M
Cash
$4.6M
Quarterly Burn
$1.4M
Runway
9.9 mo
Revenue
$222K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| eligen b12 | Approved |
| eligen b12 rx | Approved |
| oral eligen b12 | Approved |
| oral semaglutide | Phase 3 |
Frequently asked questions
How many drug candidates are in EMISPHERE TECHNOLOGIES INC's pipeline?
EMISPHERE TECHNOLOGIES INC (EMIS) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is EMISPHERE TECHNOLOGIES INC's lead drug candidate?
EMISPHERE TECHNOLOGIES INC's most advanced tracked candidate is eligen b12 (Approved) for Vitamin B12 deficiency.
What is EMISPHERE TECHNOLOGIES INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, EMISPHERE TECHNOLOGIES INC has approximately 9.9 months of cash runway.
What is EMISPHERE TECHNOLOGIES INC's market capitalization?
EMISPHERE TECHNOLOGIES INC's market capitalization is approximately $160.1M.
Who is the CEO of EMISPHERE TECHNOLOGIES INC?
Mr. Peter Joseph Goldstein M.B.A. is the chief executive officer of EMISPHERE TECHNOLOGIES INC (EMIS).
Get the full picture on EMISPHERE TECHNOLOGIES INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.